GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
Subscribe To Our Newsletter & Stay Updated
